Pharmacological prospects in the treatment of Duchenne muscular dystrophy

Current Opinion in Neurology

Volumn 26, Issue 5, 2013, Pages 577-584

  Ruegg, Urs T ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANTIOXIDANT; ATALUREN; BIGLYCAN; CALCIUM CHANNEL; CALCIUM RELEASE ACTIVATED CALCIUM CHANNEL 1; CORTICOSTEROID; CYCLIC AMP; CYCLIC GMP; CYCLOPHILIN D; DRISAPERSEN; DYSTROPHIN; ESTROGEN RECEPTOR; ETEPLIRSEN; GENTAMICIN; HORMONE RECEPTOR; MYOSTATIN; PREDNISOLONE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RYANODINE RECEPTOR 1; SMALL NUCLEAR RNA; SOMATOMEDIN C; STEROID RECEPTOR; TAMOXIFEN; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; UTROPHIN; VANILLOID RECEPTOR 1; VANILLOID RECEPTOR 2;

BECKER MUSCULAR DYSTROPHY; CALCIUM CELL LEVEL; CALCIUM HOMEOSTASIS; CALCIUM TRANSPORT; DRUG DOSE REGIMEN; DUCHENNE MUSCULAR DYSTROPHY; EXON SKIPPING; GENE MUTATION; GENE PRODUCT; GENE TARGETING; GENE THERAPY; GENE TRANSFER; HEART MUSCLE FIBROSIS; HUMAN; MITOCHONDRION; MUSCLE STRENGTH; MYOBLAST; OXIDATIVE STRESS; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RECEPTOR POTENTIAL; REVIEW; SKELETAL MUSCLE; STEM CELL TRANSPLANTATION; STOP CODON;

ANIMALS; DYSTROPHIN; HUMANS; MUSCLE FIBERS, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; MUTATION; SIGNAL TRANSDUCTION; UTROPHIN;

EID: 84883766237     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0b013e328364fbaf     Document Type: Review

References (61)

1. Hoffman EP, Kunkel LM. Dystrophin abnormalities in Duchenne/Becker muscular dystrophy. Neuron 1989; 2:1019-1029.
2. DeLuca A. Preclinical drug tests in the mdx mouse as a model of dystrophinopathies: An overview. Acta Myol 2012; 31:40-47.
3. Partridge TA. The mdx mouse model as a surrogate for Duchenne muscular dystrophy. FEBS J 2013. [Epub ahead of print]
4. Aartsma-Rus A. Overview on DMD exon skipping. Methods Mol Biol 2012; 867:97-116.
5. Abdel-Hamid H, Clemens PR. Pharmacological therapies for muscular dystrophies. Curr Opin Neurol 2012; 25:604-608.
6. Partridge TA. Impending therapies for Duchenne muscular dystrophy. Curr Opin Neurol 2011; 24:415-422.
7. Fairclough RJ, Wood MJ, Davies KE. Therapy for Duchenne muscular dystrophy: Renewed optimism from genetic approaches. Nat Rev Genet 2013; 14:373-378.
8. Konieczny P, Swiderski K, Chamberlain JS. Gene and cell-mediated therapies for muscular dystrophy. Muscle Nerve 2013; 47:649-663.
9. Rodino-Klapac LR, Mendell JR, Sahenk Z. Update on the treatment of Duchenne muscular dystrophy. Curr Neurol Neurosci Rep 2013; 13:332.
10. Verhaart IE, Aartsma-Rus A. Gene therapy for Duchenne muscular dystrophy. Curr Opin Neurol 2012; 25:588-596.
11. De Los Angeles Beytia L, Vry J, Kirschner J, et al. Drug treatment of Duchenne muscular dystrophy: Available evidence and perspectives. Acta Myol 2012; 31:4-8.
12. Kayali R, Ku JM, Khitrov G, et al. Read-through compound 13 restores dystrophin expression and improves muscle function in the mdx mouse model for Duchenne muscular dystrophy. Hum Mol Genet 2012; 21:4007-4020.
13. Goyenvalle A, Babbs A, Wright J, et al. Rescue of severely affected dystrophin/utrophin-deficient mice through SCAAV-U7snRNA-mediated exon skipping. Hum Mol Genet 2012; 21:2559-2571.
14. Vulin A, Barthelemy I, Goyenvalle A, et al. Muscle function recovery in golden retriever muscular dystrophy after AAV1-U7 exon skipping. Mol Ther 2012; 20:2120-2133.
15. Cirak S, Feng L, Anthony K, et al. Restoration of the dystrophin-associated glycoprotein complex after exon skipping therapy in Duchenne muscular dystrophy. Mol Ther 2012; 20:462-467.
16. Seto JT, Ramos JN, Muir L. Gene replacement therapies for Duchenne muscular dystrophy using adeno-associated viral vectors. Curr Gene Ther 2012; 12:139-151.
17. Bowles DE, McPhee SW, Li C, et al. Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol Ther 2012; 20:443-455.
18. Alloush J, Weisleder N. Trim proteins in therapeutic membrane repair of muscular dystrophy. JAMA Neurol 2013; 70:928-931.
19. Weisleder N, Takizawa N, Lin P, et al. Recombinant MG53 protein modulates therapeutic cell membrane repair in treatment of muscular dystrophy. Sci Transl Med 2012; 4:1-11.
20. Tinsley JM, Fairclough RJ, Storer R, et al. Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse. PLoS One 2011; 6:e19189.
21. Amenta AR, Yilmaz A, Bogdanovich S, et al. Biglycan recruits utrophin to the sarcolemma and counters dystrophic pathology in mdx mice. Proc Natl Acad Sci U S A 2011; 108:762-767.
22. Young MF, Fallon Jr. Biglycan: A promising new therapeutic for neuromuscular and musculoskeletal diseases. Curr Opin Genet Dev 2012; 22:398-400.
23. McAdam LC, Mayo AL, Alman BA, Biggar WD. The Canadian experience with long-term deflazacort treatment in Duchenne muscular dystrophy. Acta Myol 2012; 31:16-20.
24. Griggs RC, Herr BE, Reha A, et al. Corticosteroids in Duchenne muscular dystrophy: Major variations in practice. Muscle Nerve 2013; 48:27-31.
25. Ricotti V, Ridout DA, Scott E, et al. Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy. J Neurol Neurosurg Psychiatry 2013; 84:698-705.
26. Baudy AR, Reeves EK, Damsker JM, et al. Delta-9,11 modification of glucocorticoids dissociates nuclear factor-kappa B inhibitory efficacy from glucocorticoid response element-associated side effects. J Pharmacol Exp Ther 2012; 343:225-232.
27. Reeves EK, Hoffman EP, Nagaraju K, et al. VBP15: Preclinical characterization of a novel anti-inflammatory delta 9,11 steroid. Bioorg Med Chem 2013; 21:2241-2249.
28. Dorchies OM, Reutenauer-Patte J, Dahmane E, et al. The anticancer drug tamoxifen counteracts the pathology in a mouse model of Duchenne muscular dystrophy. Am J Pathol 2013; 182:485-504.
29. Nique F, Hebbe S, Triballeau N, et al. Identification of a 4-hydroxymethyl diarylhydantoin as a selective androgen receptor modulator. J Med Chem 2012; 55:8236-8247.
30. Cozzoli A, Capogrosso RF, Sblendorio VT, et al. GLPG0492, a novel selective androgen receptor modulator, improves muscle performance in the exercised-mdx mouse model of muscular dystrophy. Pharmacol Res 2013; 72:9-24.
31. Gehrig SM, van der Poel C, Hoeflich A, et al. Therapeutic potential of pegylated insulin-like growth factor 1 for skeletal muscle disease evaluated in two murine models of muscular dystrophy. Growth Horm IGF Res 2012; 22:69-75.
32. Brisson BK, Barton ER. New modulators for IGF-1 activity within IGF-1 processing products. Front Endocrinol 2013; 42:1-6.
33. Reutenauer-Patte J, Boittin JF, Patthey-Vuadens O, et al. Urocortins improve dystrophic skeletal muscle structure and function through both PKA- and EPAC-dependent pathways. Am J Pathol 2012; 180:749-762.
34. Percival JM, Whitehead NP, Adams ME, et al. Sildenafil reduces respiratory muscle weakness and fibrosis in the mdx mouse model of Duchenne muscular dystrophy. J Pathol 2012; 228:77-87.
35. Amthor H, Hoogaars WM. Interference with myostatin/ActRIIB signaling as a therapeutic strategy for Duchenne muscular dystrophy. Curr Gene Ther 2012; 12:245-259.
36. Argiles JM, Orpi M, Busquets S, Lopez-Soriano FJ. Myostatin: More than just a regulator of muscle mass. Drug Discov Today 2012; 17: 702-709.
37. Han HQ, Zhou X, Mitch WE, Goldberg AL. Myostatin/activin pathway antagonism: Molecular basis and therapeutic potential. Int J Biochem Cell Biol 2013. [Epub ahead of print]
38. Malik V, Rodino-Klapac LR, Mendell Jr. Emerging drugs for Duchenne muscular dystrophy. Expert Opin Emerg Drugs 2012; 17:261-277.
39. Zhao X, Moloughney JG, Zhang S, et al. Orai1 mediates exacerbated calcium entry in dystrophic skeletal muscle. PLoS One 2012; 7:e49862.
40. Gailly P. TRP channels in normal and dystrophic skeletal muscle. Curr Opin Pharmacol 2012; 12:326-334.
41. Harisseh R, Chatelier A, Magaud C, et al. Involvement of TRPV2 and SOCE in calcium influx disorder in DMD primary human myotubes with a specific contribution of alpha1-syntrophin and PLC/PKC in SOCE regulation. Am J Physiol Cell Physiol 2013; 304:C881-C894.
42. Ruegg UT, Shapovalov G, Jacobson KV, et al. Store-operated channels and calcium handling in muscular dystrophy. In: Groschner K, Graier WF, Romanin C, editors. Store-operated calcium entry (SOCE) pathways. Vienna: Springer; 2012. pp. 449-457.
43. Ito N, Ruegg UT, Kudo A, et al. Activation of calcium signaling through TRPV1 by nNOS and peroxynitrite as a key trigger of skeletal muscle hypertrophy. Nat Med 2013; 19:101-106.
44. Marx SO, Marks AR. Dysfunctional ryanodine receptors in the heart: New insights into complex cardiovascular diseases. J Mol Cell Cardiol 2013; 58:225-231.
45. Andersson DC, Meli AC, Reiken S, et al. Leaky ryanodine receptors in betasarcoglycan deficient mice: A potential common defect in muscular dystrophy. Skelet Muscle 2012; 2:2-9.
46. Iwata Y, Ohtake H, Suzuki O, et al. Blockade of sarcolemmal TRPV2 accumulation inhibits progression of dilated cardiomyopathy. Cardiovasc Res 2013. [Epub ahead of print]
47. Ito N, Ruegg UT, Kudo A, et al. Capsaicin mimics mechanical load-induced intracellular signaling events: Involvement of TRPV1-mediated calcium signaling in induction of skeletal muscle hypertrophy. Channels 2013; 7:221-224.
48. Ferrer-Montiel A, Fernandez-Carvajal A, Planells-Cases R. Advances in modulating thermosensory TRP channels. Expert Opin Ther Pat 2012; 22:999-1017.
49. Giorgio V, von Stockum S, Antoniel M, et al. Dimers of mitochondrial ATP synthase form the permeability transition pore. Proc Natl Acad Sci U S A 2013; 110:5887-5892.
50. Reutenauer J, Dorchies OM, Patthey-Vuadens O, et al. Investigation of Debio-025, a cyclophilin inhibitor, in the dystrophic mdx mouse, a model for Duchenne muscular dystrophy. Br J Pharmacol 2008; 155:574-584.
51. Wissing ER, Millay DP, Vuagniaux G, et al. Debio-025 is more effective than prednisone in reducing muscular pathology in mdx mice. Neuromuscul Disord 2010; 20:753-760.
52. Kirschner J, Schessl J, Schara U, et al. Treatment of Duchenne muscular dystrophy with ciclosporin A: A randomised, double-blind, placebo-controlled multicentre trial. Lancet Neurol 2010; 9:1053-1059.
53. Jahnke VE, Van Der Meulen JH, Johnston HK, et al. Metabolic remodeling agents show beneficial effects in the dystrophin-deficient mdx mouse model. Skelet Muscle 2012; 2:16.
54. Gehrig SM, van der Poel C, Sayer TA, et al. HSP72 preserves muscle function and slows progression of severe muscular dystrophy. Nature 2012; 484: 394-398.
55. Shirokova N, Niggli E. Cardiac phenotype of Duchenne muscular dystrophy: Insights from cellular studies. J Mol Cell Cardiol 2013; 58:217-224.
56. Ismail HM, Ruegg UT, Dorchies OM, et al. Diapocynin inhibits ROS production and prevents force loss in eccentrically contracting dystrophic muscle. PLoS One (in press).
57. Kim JH, Kwak HB, Thompson LV. Contribution of oxidative stress to pathology in diaphragm and limb muscles with Duchenne muscular dystrophy. J Muscle Res Cell Motil 2013; 34:1-13.
58. Terrill JR, Radley-Crabb HG, Grounds MD, Arthur PG. N-acetylcysteine treatment of dystrophic mdx mice results in protein thiol modifications and inhibition of exercise induced myofibre necrosis. Neuromuscul Disord 2012; 22:427-434.
59. Nakae Y, Dorchies O, Stoward P, et al. Quantitative evaluation of the beneficial effects in the mdx mouse of epigallocatechin gallate, an antioxidant polyphenol from green tea. Histochem Cell Biol 2012; 137:811-827.
60. Mahler A, Mandel S, Lorenz M, et al. Epigallocatechin-3-gallate: A useful, effective and safe clinical approach for targeted prevention and individualised treatment of neurological diseases?. EPMA J 2013; 4:5.
61. Kim JH, Lawler JM. Amplification of proinflammatory phenotype, damage, and weakness by oxidative stress in the diaphragm muscle of mdx mice. Free Radic Biol Med 2012; 52:1597-1606.